Land: Verenigde Staten
Taal: Engels
Bron: NLM (National Library of Medicine)
NORGESTIMATE (UNII: C291HFX4DY) (NORGESTIMATE - UNII:C291HFX4DY), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)
Sandoz Inc
NORGESTIMATE
NORGESTIMATE 0.18 mg
PRESCRIPTION DRUG
Tri-Lo-EstaryllaTM (norgestimate and ethinyl estradiol tablets) are indicated for use by females of reproductive potential to prevent pregnancy [see CLINICAL STUDIES (14)]. Do not prescribe norgestimate and ethinyl estradiol to women who are known to have the following conditions: There is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to low dose COCs prior to conception or during early pregnancy. Do not administer COCs to induce withdrawal bleeding as a test for pregnancy. Do not use COCs during pregnancy to treat threatened or habitual abortion. Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is we
Tri-Lo-EstaryllaTM (norgestimate and ethinyl estradiol tablets, USP) are available in a blister card: Each blister card (28 tablets) contains in the following order:
Abbreviated New Drug Application
TRI-LO- ESTARYLLA- NORGESTIMATE AND ETHINYL ESTRADIOL SANDOZ INC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TRI-LO-ESTARYLLA SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TRI-LO-ESTARYLLA . T RI-LO -ESTARYLLA (NORGESTIMATE AND ETHINYL ESTRADIOL TABLETS) FOR ORAL USE INITIAL U.S. APPROVAL: 1989 WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • • RECENT MAJOR CHANGES RECENT MAJOR CHANGES Contraindications (4) 08/2017 Warnings and Precautions (5.3) 08/2017 INDICATIONS AND USAGE T ri-Lo-Estarylla (norgestimate and ethinyl estradiol tablets) is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. (1.1) DOSAGE AND ADMINISTRATION • • • DOSAGE FORMS AND STRENGTHS T ri-Lo-Estarylla consists of 28 round, coated tablets in the following order (3): • • • • CONTRAINDICATIONS • • • • • • WARNINGS AND PRECAUTIONS • TM TM TM NORGESTIMATE AND ETHINYL ESTRADIOL IS CONTRAINDICATED IN WOMEN OVER 35 YEARS OLD WHO SMOKE. (4) CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS FROM COMBINATION ORAL CONTRACEPTIVES (COC) USE. (4) Contraindications (4) 08/2017 Warnings and Precautions (5.3) 08/2017 TM Take one tablet daily by mouth at the same time every day. (2.2) Take tablets in the order directed on the blister pack. (2.2) Do not skip or delay tablet intake. (2.2) TM 7 white tablets each containing 0.18 mg norgestimate and 0.025 mg ethinyl estradiol. 7 light blue tablets each containing 0.215 mg norgestimate and 0.025 mg ethinyl estradiol. 7 blue tablets each containing 0.25 mg norgestimate and 0.025 mg ethinyl estradiol. 7 green tablets (inert). A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Pregnancy (4) Breast cancer or other estrogen- or progestin-sensitive cancer (4) Co-administration with Hepatitis C drug combina Lees het volledige document